The second decade of synthetic biology: 2010–2020

Fankang Meng1,2 & Tom Ellis1,2,3✉

Synthetic biology is among the most hyped research topics this century, and in 2010 it entered its teenage years. But rather than these being a problematic time, we’ve seen synthetic biology blossom and deliver many new technologies and landmark achievements.

In 2020 synthetic biology turned 20 years old. It’s first decade saw some impressive research papers, lots of visionary thinking and unprecedented excitement, but its second decade—from 2010 to 2020—was when the hype really needed to be replaced by some real achievements. So how has it done?

The decade got off to a great start. Looking back at 2010, the biggest synthetic biology story of the year was the complete synthesis of a working bacterial genome by a team at the J. Craig Venter Institute (JCVI)1. A landmark achievement that showed that DNA synthesis and DNA assembly could be scaled to megabase size, delivering on some of the biggest ambitions from the start of the century. However, just scaling DNA construction would not be enough to deliver the field’s many other ambitions. 2010 also saw the publication of ‘Five Hard Truths for Synthetic Biology’ a critical article that examined how the lack of progress on engineering ambitions was slowing efforts to deliver on promises of reliability, standardisation and automated design2. These were indeed problems for the field, and were highlighted in one of the first synthetic biology papers in Nature Communications which showed a robust genetic logic gate failing when moved into different E. coli strains3. Could hard biological problems such as context, noise, burden and cross-reactivity really be solved to allow us to engineer cells like we wire-up electronic circuits?

Well thanks to a lot of challenging technical biology and biological engineering work undertaken by many in the field, but especially MIT’s Chris Voigt, the answer to this was yes. In 2016 Nielsen et al., published Cello, a remarkable end-to-end computer aided design system for logic circuit construction in E. coli4. Of all the papers in the last decade, this is probably the most satisfying for hardcore synthetic biologists as it realises so much of the promised engineering of biology and does so through standardisation, characterisation and automated design. It’s no coincidence that in the years preceding this paper Voigt’s team worked tirelessly on delivering so many other foundational papers on E. coli synthetic biology, giving us algorithmic design of genetic parts, and professional characterisation of part libraries. While it is easy to focus on the many big landmark achievements of synthetic biology (Fig. 1), what has really helped the field deliver on the hype more than anything else has been a lot of hard technical work to improve our design and understanding of genetic parts alongside innovation and the discovery of new technologies that let us write, build, edit and share DNA code better than ever (Fig. 2).

Indeed, looking back 10 years what is most striking is how the methods and tools have changed for those engineering life. Many groups were still reliant on the iGEM competition for...
exchanging their DNA parts. These could only be assembled
serially by BioBrick cloning, and performance data on these parts
was rarely reliable. Building a genetic construct was slow lab work
and typically resulted in failure when added into a cell. Methods
to fix a DNA construct once inside a cell were severely lacking
and in high demand. It’s no surprise therefore, that synthetic
biology groups were the first to pounce on gene editing tech-
ologies like CRISPR as they appeared in 2011 and 2012. Since
2006, George Church’s lab had been pursuing a project to mutate
every TAG stop codon to TAA in E. coli to free up a codon for an
extra amino acid5, and so unsurprisingly they were very inter-
ested in developing any technology that can precisely alter DNA
inside a cell. His group and his former postdoc published the first
two papers in 2013 showing CRISPR being used in eukaryotic
cells and developed many further innovations of CRISPR in the
following years, including CRISPR-based gene drives. Synthetic
biology groups in California were also quick to turn CRISPR into
more than just a cutting tool, inventing the now ubiquitous dCas9
as a programmable binder of DNA to enable customisable gene
regulation6.

While there’s no doubt that CRISPR was the breakthrough of
the decade in biosciences, it’s perhaps its forerunner TALENs
(TAL-Effector Nucleases) that deserve more credit in revolutio-
nizing how synthetic biology changed in the past 10 years. The
promise of modular, programmable binding of any DNA
sequence and an in vivo gene editing method lured many towards
this new technology in 2011. But the large highly-repetitive nat-
ure of TALENs was a slap in the face for anyone used to standard
DNA cloning methods, PCR or even Gibson Assembly. If you
wanted to work with TALENs you needed to either buy a lot of
synthesised DNA, become an expert in robot-based DNA
assembly automation, or get your hands on a Golden Gate

Fig. 1 Landmark research achievements of synthetic biology from 2010 to 2020. A timeline is shown for the decade with brief summaries of some of the key research milestones published for each year.
Fig. 2 New enabling technologies and ways of working that have accelerated the design-build-test-learn cycle of synthetic biology in the last decade. Diagram shows the engineering cycle used in synthetic biology (centre) with cartoons illustrating some of the key technologies and ways of working that now help accelerate each phase of the cycle.

Assembly TALEN cloning toolkit from Addgene. Fortunately for synthetic biology, many people in the field tried one, two, or even all three of these things and soon began to see how much faster DNA assembly can proceed. Golden Gate DNA Assembly now rightly dominates the field and the many modular cloning (MoClo) toolkits and genetic part libraries shared via Addgene have transformed the way people work and build upon each other’s findings. Companies and academic institutions have set up dedicated facilities for automated DNA cloning and perhaps most importantly, DNA synthesis costs have fallen to the point where ordering a custom-made gene is now often more cost-efficient than trying to clone it. Such an enabling drop in price cannot be underestimated for how it changes people’s way of working for the better.

The drop in cost for gene synthesis can mostly be attributed to new methods for printing thousands of oligonucleotides in parallel on chips to make ‘oligo pools’ and teaming this with next generation sequencing (NGS) as a much more cost-effective method for validating assembled DNA. These two technologies also opened the door to a major change in the way people worked in synthetic biology, suddenly making it cost effective to design, build and measure in parallel hundreds of thousands of genetic designs in one experiment. If you can tie the output of your genetic design to an NGS-compatible measurement (e.g. barcoded RNASeq) then data analysis becomes your new bottleneck, not design and assembly as before. This has led to a major shift in the relationship between mathematical approaches and biology in synthetic biology over the decade. When making and testing DNA constructs was slow and expensive in the 2000s, mathematical modelling was valuable to predict successes and failures, and to narrow down the design space. Now this approach is rarely needed, and mathematical analysis instead finds its value in statistical analysis of large data sets and using this to learn how to design DNA.

High-power computation also opened up new frontiers in what can be modelled and predicted in the last 10 years. Rational design of proteins, spearheaded by David Baker’s group, came on leaps and bound, and ended the decade as part of gene circuitry in living yeast cells. The first ever whole cell model, for *Mycoplasma genitalium*, was released, enabling simulation of the effects of hundreds of genes through a cell cycle. This helped inform JCVI’s project towards a minimal genome, which delivered a further landmark in 2016 with the impressive engineering of a bacteria with a minimized synthetic genome.

Synthetic genomics also moved into eukaryotes with the international Sc2.0 consortium constructing highly-modified, yet fully-functional synthetic versions of Baker’s yeast chromosomes. *E. coli* also ended the decade with a synthetic genome, redesigned and constructed to remove all use of 3 of the 64 codons of the genetic code. Such recoding enables cells to be engineered to readily insert non-standard amino acids into proteins as desired. This was pioneered by the Church lab’s mutation-based approach that reduced *E. coli* to using only 63 codons earlier in the decade, demonstrating expansion of the genetic code. Expansion of this code was also achieved in *E. coli* by addition of bases of DNA beyond just A, T, C and G.

DNA also became a way to store data, initially just in vitro via chemical synthesis, but then also in cells via ‘molecular recorder’ genetic systems that use recombinases or CRISPR to modify DNA as cells grow, divide and change their gene expression. Sensing and recording in cells even went into the body, with gut bacteria sensing and reporting on events inside mice. Engineered probiotic bacteria were made that detect cancer in urine and others turned them into therapies, correcting metabolic disorders and sensing and destroying pathogens. The hottest cell-based therapies in the pharma industry, cancer-targeting CAR-T cells, also started to be equipped with sensing and logic devices from synthetic biology. Sensing and logic with synthetic biology also found further healthcare applications, including paper-based biosensors that could be rapidly designed to detect RNA from pathogens like Ebola and Zika. These sensors, along with other recent applications, were enabled by new modular ways to design complex nucleic acid interactions, such as toehold switches, and by a new ‘cell-free’ way to do synthetic biology, using lysates from cells as customisable and accessible alternatives to in-cell engineering.

Healthcare has now arguably replaced metabolic engineering as the go-to for synthetic biology applications, but that has not stopped progress in this area too. Academic achievements include engineering cells to fix CO2 and nitrogen, and getting yeast to make opioids and cannabinoids. Biofoundries have been established at many institutes and can demonstrate rapid engineering of cells for biosynthesis of dozens of different molecules. Of course, much of the work in using synthetic biology for metabolic engineering now happens at companies like Amyris, Genomatica, Ginkgo and Zymergen.

Looking back on the decade, the many research landmarks and new directions for synthetic biology are indeed very impressive, but as synthetic biology researchers it’s the advances in enabling technologies that excite us the most as these unlock what can
come next. However, if we’re to look for the single biggest achievement of the decade that justifies the hype of the field back in 2010, then we can look no further than the proliferation and valuations of the hundreds of synthetic biology companies around the world. A multibillion dollar industry now exists that makes chemicals, drugs, proteins, probiotics, sensors, fertilisers, textiles, food and many other things from engineered cells. And these are not existing companies just buying into synthetic biology, but companies founded, led and grown by the postdocs, PhDs and iGEM students who research at the bench and in most cases have worked in this field their entire adult lives.

Received: 10 August 2020; Accepted: 16 September 2020; Published online: 14 October 2020

References
1. Gibson, D. G. et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 329, 52–56 (2010).
2. Kwok, R. Five hard truths for synthetic biology. Nature 463, 288–290 (2010).
3. Wang, B., Kitney, R. I., Joly, N. & Buck, M. Engineering modular and orthogonal genetic logic gates for robust digital-like synthetic biology. Nat. Commun. 2, 508 (2011).
4. Nielsen, A. A. K. et al. Genetic circuit design automation. Science 352, aac7341 (2016).
5. Lajoie, M. J. et al. Genomically recoded organisms expand biological functions. Science 342, 357–360 (2013).
6. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).
7. Cambray, G., Guimarães, J. C. & Arkin, A. P. Evaluation of 244,000 synthetic sequences reveals design principles to optimize translation in Escherichia coli. Nat. Biotechnol. 36, 1005–1015 (2018).
8. Ng, A. H. et al. Modular and tunable biological feedback control using a de novo protein switch. Nature 572, 265–269 (2019).
9. Karr, J. R. et al. A whole-cell computational model predicts phenotype from genotype. Cell 150, 389–401 (2012).
10. Hutchison, C. A. 3rd et al. Design and synthesis of a minimal bacterial genome. Science 351, aad6253 (2016).
11. Richardson, S. M. et al. Design of a synthetic yeast genome. Science 355, 1040–1044 (2017).
12. Fredens, J. et al. Total synthesis of Escherichia coli with a recoded genome. Nature 569, 514–518 (2019).
13. Pardee, K. et al. Paper-based synthetic gene networks. Cell 159, 940–954 (2014).
14. Tinaraf, A., Jaenes, K. & Pardee, K. Synthetic biology goes cell-free. BMC Biol 17, 64 (2019).
15. Casini, A. et al. A pressure test to make 10 molecules in 90 days: external evaluation of methods to engineer biology. J. Am. Chem. Soc. 140, 4302–4316 (2018).

Acknowledgements
We wish to thank everyone who engaged with a July 2020 Twitter conversation on the most important achievements in synthetic biology from the last 10 years which helped to shape this article. A link to this conversation is here: https://twitter.com/ProfTomEllis/status/128098328879746444.

Author contributions
F.M. designed and produced the figures. T.E. wrote the manuscript text.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.E.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020